NEW YORK, NY -- (Marketwired) -- 02/25/14 -- Kadmon Corporation, LLC, today announced the execution of a co-promotion agreement between its wholly-owned subsidiary, Kadmon Pharmaceuticals, LLC, and Valeant Pharmaceuticals North America, LLC in which Kadmon has been granted U.S. rights to co-promote SYPRINE® (trientine hydrochloride) Capsules (the "Product"), a chelation therapy indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Kadmon will co-promote the Product through its sales force and extensive network of specialty pharmacies. Financial terms of the agreement were not disclosed.
Wilson's disease is a rare genetic disorder resulting from mutations in the gene required for copper transport in the liver (ATP7B). The manifestation of the disease results from a failure of the copper excretory pathway that leads to toxic accumulation of copper in the liver and eventually other organs. The condition can be effectively treated with chelating agents which bind copper to facilitate its excretion from the body.
"This agreement adds an important new therapy to our growing commercial business, expanding its focus beyond the treatment of Hepatitis C," said Samuel D. Waksal, Ph.D., Chairman and CEO of Kadmon. "By utilizing our commercial platform to raise awareness of Wilson's disease through increased education, promotion and distribution of SYPRINE, we believe we can better serve patients with this rare genetic disorder. This is an important step in expanding the scope of our commercial reach, which we will continue to grow through further commercial agreements as we develop our pipeline of product candidates. We are focused on developing drugs that have a profound impact on diseases for which there are no alternative therapies, predominantly in the areas of oncology, inflammatory disorders and rare genetic diseases."
Please see SYPRINE full prescribing information, including Most Serious Side Effects, for additional Important Safety Information.
About Kadmon Corporation
Kadmon Corporation, LLC, is a global company built on a 21st-century paradigm for the translation of innovative science into treatment. The company currently offers products and services for the treatment and management of hepatitis C, and is pioneering novel medicines in areas of serious disease, including oncology, infectious diseases, immunology and neurodegenerative diseases. Emphasizing emerging concepts in molecular biology and genomics, Kadmon is developing treatments and treatment combinations that target the metabolomics and signaling pathways associated with disease, with the goal of addressing some of today's most pressing areas of unmet medical need. For more information, visit www.kadmon.com.
This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.